APA (7th ed.) Citation

Subramanian, R., Wang, J., Murray, B., Custodio, J., Hao, J., Lazerwith, S., . . . Smith, B. J. (2022). Human pharmacokinetics prediction with an in vitro-in vivo correction factor approach and in vitro drug-drug interaction profile of bictegravir, a potent integrase-strand transfer inhibitor component in approved biktarvy® for the treatment of HIV-1 infection. Xenobiotica, 52(12), 1020-1030. https://doi.org/10.1080/00498254.2023.2169207

Chicago Style (17th ed.) Citation

Subramanian, Raju, et al. "Human Pharmacokinetics Prediction with an In vitro-in vivo Correction Factor Approach and In vitro Drug-drug Interaction Profile of Bictegravir, a Potent Integrase-strand Transfer Inhibitor Component in Approved Biktarvy® for the Treatment of HIV-1 Infection." Xenobiotica 52, no. 12 (2022): 1020-1030. https://doi.org/10.1080/00498254.2023.2169207.

MLA (9th ed.) Citation

Subramanian, Raju, et al. "Human Pharmacokinetics Prediction with an In vitro-in vivo Correction Factor Approach and In vitro Drug-drug Interaction Profile of Bictegravir, a Potent Integrase-strand Transfer Inhibitor Component in Approved Biktarvy® for the Treatment of HIV-1 Infection." Xenobiotica, vol. 52, no. 12, 2022, pp. 1020-1030, https://doi.org/10.1080/00498254.2023.2169207.